1265295-20-2
1265295-20-2
Chemical Structure
MRE-269-d7
Synonym(s): ACT-333679-d7
- CAS No.: 1265295-20-2
- Formula:C25H22D7N3O3
- Molecular Weight:426.56
IUPAC Name: 2-(4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl-d7)amino)butoxy)acetic acid
InChIKey: OJQMKCBWYCWFPU-HXAWLNHQSA-N
SMILES: OC(COCCCCN(C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)=O
Biological Activity: MRE-269-d7 is deuterium labeled MRE-269 (HY-79593). MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MRE-269-d7 | 99.59% | MRE-269-d7 is deuterium labeled MRE-269 (HY-79593). MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MRE-269 (Standard) | ≥98% | MRE-269 (Standard) is the analytical standard of MRE-269. This product is intended for research and analytical applications. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MRE-269-d7 sodium | MRE-269-d7 (ACT-333679-d7) sodium is deuterium-labeled MRE-269 (HY-79593). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MRE-269-d6 | MRE-269-d6 is deuterium labeled MRE-269. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MRE-269 | 99.14% | MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. Eur J Pharmacol. 2017 Jan 15;795:75-83. [Content Brief]
